Bexicaserin
Developmental and Epileptic Encephalopathy
Longboard PharmaceuticalsSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Developmental and Epileptic Encephalopathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)- Zogenix, Inc. | Phase 3 | BB |
Elsunersen Praxis Precision Medicines | Phase 3 | B |
Nbi-827104 Neurocrine Biosciences | Phase 2 | CCC |
MELATONIN Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | Phase 2 | CCC |
Soticlestat Takeda | Phase 1/2 | CCC |
View all 9 →
Same molecule, other indications
Bexicaserin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →